Airway Cell-State Diversity in Severe Lung Disease: Clinical Implications and Emerging Insights

Abstract

Severe lung diseases such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and severe asthma are characterized by extensive airway remodeling, inflammation, and progressive loss of function. Recent advances in single-cell RNA sequencing and spatial transcriptomics have revealed remarkable heterogeneity in airway epithelial and immune cell states within diseased lungs. This review synthesizes current understanding of airway cell-state diversity, outlines its pathophysiological significance, and discusses the clinical implications for diagnosis, treatment, and future research. By integrating mechanistic insights and the latest clinical guidelines, this article aims to provide healthcare professionals with a comprehensive overview of how cell-state heterogeneity shapes the course and management of severe lung disease.

Introduction

Airway diseases represent a major global health burden, with severe forms often leading to substantial morbidity and mortality. Historically, the airway epithelium was viewed as a uniform barrier, but recent research has fundamentally changed this perspective, revealing a dynamic ecosystem of epithelial, immune, and stromal cells, each capable of adopting discrete functional states. This diversity is especially pronounced in severe lung diseases, where cell-state plasticity contributes to pathogenesis, treatment response, and disease progression. Understanding the biological and clinical implications of airway cell-state diversity is critical for optimizing patient care and advancing therapeutic development.

Epidemiology / Disease Burden

Lung diseases such as COPD, IPF, and severe asthma collectively affect hundreds of millions globally. COPD alone is the third leading cause of death worldwide. Hospitalization rates for acute exacerbations continue to rise, highlighting the urgent need for improved diagnostics and therapies. Severe disease phenotypes are associated with frequent exacerbations, rapid lung function decline, and poor quality of life. Epidemiological studies increasingly indicate that patient outcomes are closely linked to underlying airway cellular heterogeneity, suggesting that cell-state diversity may serve as both a biomarker and therapeutic target.

Pathophysiology

Airway cell-state diversity encompasses distinct phenotypic and functional subsets within epithelial, immune, and mesenchymal compartments. In severe lung disease, the airway epithelium transitions from a homeostatic to a pathological state, characterized by aberrant basal cell expansion, loss of differentiation, and emergence of transitional or metaplastic cell populations. Goblet cell hyperplasia, ciliated cell loss, and squamous metaplasia have been documented in both COPD and IPF. Immune cell diversity is equally notable, with altered proportions of macrophage subtypes, dysfunctional regulatory T cells, and the accumulation of pro-fibrotic fibroblasts. Single-cell analyses have identified unique cell states—such as KRT5+ basal-like cells and transitional club cells—that are associated with disease severity and fibrotic remodeling. These changes are driven by chronic injury, dysregulated signaling (e.g., TGF-β, WNT, Notch), and persistent inflammation, ultimately resulting in impaired mucociliary clearance, defective repair, and progressive fibrosis.

Risk Factors

Key risk factors for severe lung disease and associated airway cell-state alterations include chronic smoking, occupational exposures (e.g., silica, asbestos), genetic susceptibility (e.g., alpha-1 antitrypsin deficiency), advanced age, and repeated respiratory infections. Environmental factors such as air pollution exacerbate epithelial and immune cell dysfunction. Genetic and epigenetic factors influence the propensity of airway cells to adopt pathological states, with emerging evidence implicating single nucleotide polymorphisms (SNPs) in genes regulating epithelial integrity and immune regulation. Comorbidities such as systemic autoimmune diseases further modulate airway cell-state landscapes.

Clinical Features

Patients with severe lung disease exhibit chronic cough, progressive dyspnea, frequent exacerbations, and declining lung function. The clinical heterogeneity observed often mirrors the underlying cellular diversity, with distinct cell-state profiles correlating with phenotypes such as steroid resistance in severe asthma, rapid decline in IPF, or frequent exacerbator status in COPD. Sputum cytology and bronchoalveolar lavage studies have revealed varied proportions of goblet cells, neutrophils, eosinophils, and transitional epithelial cells, which may guide personalized management strategies.

Diagnosis

Diagnosis of severe lung disease relies on a combination of clinical assessment, spirometry, imaging, and increasingly, molecular and cellular profiling. Advances in single-cell sequencing and multiplex imaging allow for high-resolution mapping of airway cell states in tissue biopsies, providing potential biomarkers for disease stratification. Bronchoscopic sampling and non-invasive biomarkers (e.g., exhaled breath condensate, sputum) are under investigation for their utility in capturing airway cell-state changes and predicting disease progression or therapeutic response.

Treatment & Management

Current management of severe lung disease is guided by disease phenotype and severity. Inhaled corticosteroids, bronchodilators, and antifibrotic agents remain the mainstays for COPD, asthma, and IPF, respectively. However, response to therapy is often variable, reflecting underlying cell-state heterogeneity. Personalized medicine approaches that incorporate cell-state biomarkers may improve therapeutic efficacy. Non-pharmacologic interventions such as pulmonary rehabilitation and smoking cessation are crucial adjuncts. In select cases, lung transplantation may be considered for end-stage disease.

Recent Advances / Emerging Therapies

Recent advances have focused on targeting specific airway cell states and their signaling pathways. Novel therapeutics include inhibitors of TGF-β and WNT pathways, agents targeting aberrant basal-like cell expansion, and biologics directed against key inflammatory mediators. Cell-based therapies, such as the transplantation of healthy epithelial progenitors or gene editing to restore normal cell-state dynamics, are in early-phase clinical trials. Integration of single-cell data with clinical phenotyping holds promise for the development of precision medicine approaches tailored to individual airway cell-state profiles.

Guideline Recommendations

International guidelines (e.g., GOLD, ATS/ERS, GINA) increasingly recognize the heterogeneity of severe lung disease and advocate for phenotype-driven management. While routine clinical assessment of airway cell-state diversity is not yet standard practice, ongoing research may soon enable its incorporation into diagnostic and therapeutic algorithms. Current guidelines emphasize the importance of early diagnosis, risk factor modification, and individualized therapy to optimize outcomes in severe disease.

Conclusion

Airway cell-state diversity represents a critical determinant of pathogenesis, clinical phenotype, and therapeutic response in severe lung disease. Advances in single-cell technologies have deepened our understanding of these complex ecosystems, paving the way for novel diagnostics and targeted treatments. Clinicians should remain abreast of emerging evidence, as the integration of cell-state biomarkers into routine care holds significant potential to improve patient outcomes in the years ahead.